An adjuvant autologous therapeutic vaccine %25252528HSPPC-96…
An adjuvant autologous therapeutic vaccine %25252528HSPPC-96%2525253B vitespen%25252529 versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma%2525253A a multicentre%2525252C open-label%2525252C randomised phase III trial.
Article, Chapter
Full text availability for this item
Journal:
Lancet, TheOpens in new Window
Coverage:
- 1823-10-05~present; volume:1~present;issue:1~present